FDAnews Device Daily Bulletin

IGI EXTENDS DELIVERY TECHNOLOGY RIGHTS FOR TEN ADDITIONAL YEARS

Dec. 16, 2005
A A

IGI, Inc. announces today that it has extended until December 2015 its exclusive license from Novavax (NVAX) for the use of Novasome(R) lipid vesicle encapsulation technology, micellar nano-particles, and the Ultrasponge(R) Technology. The technologies are for use in human dermatological products for localized usage at the delivery zone, including cosmetics, consumer products, photographic chemicals and other specialty chemicals, which include blood substitutes containing hemoglobin and other oxygen carrying materials; and processes for making the same.

Business Wire (http://home.businesswire.com/portal/site/google/index.jsp?ndmViewId=news_view&newsId=20051213005611&newsLang=en)